Olimel N9 (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

The blend delivers a balanced set of amino acids directly into the bloodstream, where they serve as building blocks for protein synthesis, precursors for metabolic pathways, and regulators of nitrogen balance. By bypassing the gastrointestinal tract, the formulation quickly restores amino acid availability for cellular repair and metabolic functions.

The prescribed dose of Olimel N9 is determined by the treating physician based on the patient’s weight, clinical condition, and nutritional goals. Dosing is individualized and calculated to meet the required protein and nitrogen needs, typically expressed in grams of amino acids per kilogram of body weight per day.

Safety data for intravenous amino acid mixtures in pregnancy and lactation are limited. Use is generally reserved for situations where the benefit to the mother outweighs potential risks to the fetus or infant, and it should be prescribed by a specialist familiar with maternal‑fetal medicine.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Olimel N9 offers a comprehensive profile of ten amino acids in a single sterile powder, providing a balanced formulation comparable to other commercial amino acid blends. Differences may lie in individual amino‑acid concentrations, osmolarity, and compatibility with lipid emulsions, which clinicians consider when selecting a product for specific patient needs.

Store Olimel N9 at ambient temperature, protected from moisture and direct sunlight, in its original sealed container. Avoid freezing and ensure the product is reconstituted with the appropriate diluent under aseptic conditions before intravenous administration.

Olimel N9 is supplied as a sterile powder that must be reconstituted with a compatible diluent and administered intravenously, usually via a controlled infusion pump. The infusion rate is set by the prescribing clinician according to the patient’s nutritional plan and clinical status.

Serious risks include severe hypersensitivity reactions, metabolic acidosis, significant electrolyte disturbances, renal function worsening, and thrombophlebitis at the infusion site. Prompt monitoring and immediate medical intervention are essential if any of these events occur.

Patients with known hypersensitivity to any component of the formulation, uncontrolled severe electrolyte imbalances, or those for whom intravenous amino acid therapy is contraindicated should not receive Olimel N9. Clinical judgment is required to assess suitability on a case‑by‑case basis.